By studying a common virus and a rare cancer, Ohio State researchers have developed a treatment that could improve outcomes for some lymphoma patients. A new treatment regimen developed at the OSUCCC &ndash; James may offer promising results for a rare form of lymphoma courtesy of therapies for the Epstein-Barr virus &ndash;&nbsp;a virus carried by more than 90 percent of people. Through the administration of those anti-viral medicines, researchers found that they could &ldquo;program&rdquo; CNS lymphoma cells to self-destruct. &ldquo;Thus far, 23 patients have been treated, most of whom, to this date, have been cured. There&rsquo;s been an overall response rate of more than 95 percent,&rdquo; Robert Baiocchi, MD, PhD, says. &ldquo;It&rsquo;s a very aggressive disease, and this is a good treatment option for people who don&rsquo;t want to undergo aggressive chemotherapy.\"